Sweden

Cabometyx in Europe

Contact
This is a promotional website intended for Healthcare Professionals in Sweden
Abbreviations
Safety Information
SmPC

CABOMETYX® (cabozantinib) and Hepatocellular Carcinoma Guidelines

Current clinical practice guidelines for the management of hepatocellular carcinoma (HCC) include those produced by the European Society for Medical Oncology (ESMO),11 updated in 201912, the European Association for the Study of the Liver (EASL), updated in 201813 and the National Comprehensive Cancer Network (NCCN), updated in 2019.14

Cabozantinib and the ESMO HCC guidelines

Strongly recommended (Grade I, A) as a second-line treatment for advanced HCC.11

For more info about the latest ESMO clinical practice guidelines on the diagnosis, treatment and follow-up of hepatocellular carcinoma:

Cabozantinib and the EASL HCC guidelines

Strong recommendation with a high level of evidence as a second-line treatment for advanced HCC.13

For more info about the EASL guidelines on the management of hepatocellular carcinoma:

Cabozantinib and the NCCN HCC guidelines

Recommended as a Category 1 (high level of evidence) second-line treatment for HCC.14

For more info about the NCCN guidelines on hepatobiliary cancers:

 
References
© Ipsen Group 2020 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to Cabometyx.se website. This website is intended for Sweden Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.

 

I AM A SWEDEN HEALTHCARE PROFESSIONAL

I AM A EU HEALTHCARE PROFESSIONAL

I AM NOT A SWEDEN HEALTHCARE PROFESSIONAL